Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor-the importance of gastrointestinal pH and solubility for the in vivo exposure

Drug Development and Industrial Pharmacy

Volumn 37, Issue 9, 2011, Pages 1036-1042

  Sigfridsson, Kalle ^a,b   Lundqvist, Anders ^a   Strimfors, Marie ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Dissolution rate; Gastric pH; Nanosuspension; Pharmacokinetic; Poorly soluble; Proton pump inhibitor; Suspension

Indexed keywords

BA99; CHEMICAL COMPOUND; LINAPRAZAN; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FEMALE; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; RAT; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; DRUG COMBINATIONS; FEMALE; GASTRIC ACID; GASTROINTESTINAL TRACT; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; NANOPARTICLES; PARTICLE SIZE; PROTON PUMP INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 79961133789     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.558902     Document Type: Article

References (30)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classifcation: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
2. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. (2002). Biopharmaceutics classifcation system: the scientifc basis for biowaiver extensions. Pharm Res, 19:921-925. (Pubitemid 34804232)
3. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS et al. (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classifcation. Mol Pharm, 1:85-96.
4. Hörter D, Dressman JB. (2001). Infuence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75-87.
5. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing\oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644. (Pubitemid 47285408)
6. Gao L, Zhang D, Chen M. (2008). Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res, 10:845-862.
7. Sigfridsson K, Forssén S, Holländer P, Skantze U, de Verdier J. (2007). A formulation comparison, using a solution and diferent nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm, 67:540-547. (Pubitemid 47225040)
8. Sigfridsson K, Lundqvist AJ, Strimfors M. (2011). Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm, 37:243-251.
9. Andersson K, Carlsson E. (2005). Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ter, 108:294-307. (Pubitemid 41693765)
10. Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11 (Suppl 2):S73-S80.
11. Sutton SC. (2004). Companion animal physiology and dosage form performance. Adv Drug Deliv Rev, 56:1383-1398. (Pubitemid 38748822)
12. DeSesso JM, Jacobson CF. (2001). Anatomical and physiological parameters afecting gastrointestinal absorption in humans and rats. Food Chem Toxicol, 39:209-228. (Pubitemid 32244129)
13. Nernst W, Brunner E. (1904). Teorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physik Chemie, 47:52-110.
14. Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91-97.
15. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19. (Pubitemid 32209229)
16. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). Te role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food efect on absorption in human. Int J Pharm, 285:135-146. (Pubitemid 39361543)
17. Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309-313.
18. Dressman JB. (1986). Comparison of canine and human gastrointestinal physiology. Pharm Res, 3:123-131. (Pubitemid 17195382)
19. Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman JB et al. (2006). Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res, 23:1373-1381. (Pubitemid 43946159)
20. Jantratid E, Janssen N, Reppas C, Dressman JB. (2008). Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res, 25:1663-1676.
21. Kararli TT. (1989). Gastrointestinal absorption of drugs. Crit Rev Ter Drug Carrier Syst, 6:39-86. (Pubitemid 19189426)
22. Dressman JB, Yamada K. (1991). Animal models for oral drug absorption. In: Welling PG, Tse FLS, Dighe S V. (Eds.), Pharmaceutical Bioequivalence. Marcel Dekker, New York, pp. 235-266.
23. Watts PJ, Illum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm, 23:893-913. (Pubitemid 27406363)
24. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P et al. (2001). Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci, 12:261-269.
25. Hirasawa N, Ishise S, Miyata H, Danjo K. (2003). An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev Ind Pharm, 29:997-1004. (Pubitemid 37346101)
26. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV et al. (2004). High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev, 56:275-300. (Pubitemid 38201426)
27. Pudipeddi M, Serajuddin AT. (2005). Trends in solubility of polymorphs. J Pharm Sci, 94:929-939. (Pubitemid 40780760)
28. Serajuddin AT. (2007). Salt formation to improve drug solubility. Adv Drug Deliv Rev, 59:603-616. (Pubitemid 47285406)
29. McNamara D P, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS et al. (2006). Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res, 23:1888-1897. (Pubitemid 44200553)
30. Schultheiss N, Newman A. (2009). Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des, 9:2950-2967.